Chiome Bioscience (TSE:4583) Debt-to-Equity : 0.25 (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience Debt-to-Equity?

Chiome Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円313.6 Mil. Chiome Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円0.0 Mil. Chiome Bioscience's Total Stockholders Equity for the quarter that ended in Mar. 2024 was 円1,247.6 Mil. Chiome Bioscience's debt to equity for the quarter that ended in Mar. 2024 was 0.25.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Chiome Bioscience's Debt-to-Equity or its related term are showing as below:

TSE:4583' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.07 Max: 0.26
Current: 0.25

During the past 13 years, the highest Debt-to-Equity Ratio of Chiome Bioscience was 0.26. The lowest was 0.00. And the median was 0.07.

TSE:4583's Debt-to-Equity is ranked worse than
61.33% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs TSE:4583: 0.25

Chiome Bioscience Debt-to-Equity Historical Data

The historical data trend for Chiome Bioscience's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience Debt-to-Equity Chart

Chiome Bioscience Annual Data

Trend

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.06

0.10

0.25

Chiome Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.19	0.26	0.26	0.25	0.25

Competitive Comparison of Chiome Bioscience's Debt-to-Equity

For the Biotechnology subindustry, Chiome Bioscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chiome Bioscience's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's Debt-to-Equity falls into.

Chiome Bioscience Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Chiome Bioscience's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(291	+	0)	/	1157.723
	=	0.25

Chiome Bioscience's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(313.6	+	0)	/	1247.567
	=	0.25

Chiome Bioscience (TSE:4583) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Chiome Bioscience Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Chiome Bioscience (TSE:4583) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071

Website

http://www.chiome.co.jp

Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience (TSE:4583) Headlines

No Headlines